RSV B infection study in healthy older adults
Part of Immune system & allergy, Infections, Lungs & breathing clinical trials.
This study will safely expose healthy older adults (65-75) to a mild RSV B virus to see how their immune system responds. It may help develop better vaccines or treatments for RSV in older people.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 65 and 75 years old.
- You are generally healthy with no major heart, lung, autoimmune, or blood clotting conditions.
- You have not had a cold or respiratory infection in the past 6 weeks.
- You do not smoke or vape, and have not used nicotine products in the last 3 months.
- You do not live with or have daily close contact with young children or people with weak immune systems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new RSV vaccine to see if it is safe for healthy adults. It uses mRNA technology to help your body build protection against RSV, a common respiratory virus.
This study looks at how common RSV (a virus that can cause coughing and breathing problems) is in adults with a recent respiratory infection. If you have a cough or other cold-like symptoms and are 18 or older, you might be able to help by giving a sputum and saliva sample.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This trial tests a new RSV vaccine in adults aged 60 and older to see if it is safe and helps the immune system fight RSV. If you are generally healthy or have stable medical conditions without recent infections or vaccines, you may be eligible.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This study tests an experimental RSV vaccine (IN006) in healthy adults to check its safety and how well it triggers an immune response. It may help protect against respiratory syncytial virus (RSV), which can cause serious lung infections.
Hear when a new RSV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.